Stock Events

Stock Events

Advicenne 

€1.38
0
-€0.02-1.57% Friday 15:48

Statistics

Day High
1.43
Day Low
1.38
52W High
2.14
52W Low
1.11
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19SepExpected
Q2 2025
-0.4
-0.07
0.27
0.6
Expected EPS
N/A
Actual EPS
-0.4011291548

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3MM.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it develops and markets drugs for treating cystic fibrosis, a focus area that overlaps with Advicenne's work on kidney and metabolic disorders.
Novartis
NVS
Mkt Cap297.32B
Novartis is a global healthcare company that has a broad portfolio, including treatments for chronic kidney disease, making it a competitor.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, competing with Advicenne's products.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which affect metabolic processes similar to Advicenne's target disorders.
AMGEN
AMGN
Mkt Cap187.56B
Amgen has a diverse portfolio that includes treatments for bone and kidney diseases, areas that overlap with Advicenne's interests.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad range of products, including treatments for kidney diseases, competing in the same market as Advicenne.
Sanofi
SNY
Mkt Cap116.63B
Sanofi focuses on a wide array of therapeutic areas, including rare diseases, which puts it in competition with Advicenne.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline has a diverse pharmaceutical portfolio, including areas that compete with Advicenne's focus on kidney and metabolic disorders.

About

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Show more...
CEO
Mr. Didier Laurens
Employees
13
Country
Germany
ISIN
FR0013296746

Listings

F
DE
3MM.F
MU
DE
3MM.MU
STU
DE
3MM.STU
Grey Market
US
ADVVF

0 Comments

Share your thoughts

FAQ

What is Advicenne stock price today?▼
The current price of 3MM.STU is €1.38 EUR — it has decreased by -1.57% in the past 24 hours. Watch Advicenne stock price performance more closely on the chart.
What is Advicenne stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Advicenne stocks are traded under the ticker 3MM.STU.
Is Advicenne stock price growing?▼
3MM.STU stock has fallen by -3.36% compared to the previous week, the month change is a -24.75% fall, over the last year Advicenne has showed a -13.75% decrease.
When is the next Advicenne earnings date?▼
Advicenne is going to release the next earnings report on September 17, 2026.
What were Advicenne earnings last quarter?▼
3MM.STU earnings for the last quarter are -0.4 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Advicenne have?▼
As of April 12, 2026, the company has 13 employees.
In which sector is Advicenne located?▼
Advicenne operates in the Health & Wellness sector.
When did Advicenne complete a stock split?▼
Advicenne has not had any recent stock splits.
Where is Advicenne headquartered?▼
Advicenne is headquartered in Paris, Germany.